CN112022944A - Anticancer Chinese medicinal composition - Google Patents
Anticancer Chinese medicinal composition Download PDFInfo
- Publication number
- CN112022944A CN112022944A CN202010994142.XA CN202010994142A CN112022944A CN 112022944 A CN112022944 A CN 112022944A CN 202010994142 A CN202010994142 A CN 202010994142A CN 112022944 A CN112022944 A CN 112022944A
- Authority
- CN
- China
- Prior art keywords
- parts
- fruit
- root
- chinese
- seed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Insects & Arthropods (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an anticancer traditional Chinese medicine composition which comprises the following raw materials in parts by weight: 25-35 parts of salvia miltiorrhiza, 5-13 parts of Chinese fan palm, 6-12 parts of earthworm, 15-25 parts of dragon bone, 10-20 parts of camptotheca acuminata fruit, 5-15 parts of blackberry lily, 5-15 parts of garden balsam seed, 5-15 parts of princesplume ladysthumb fruit, 16-24 parts of clematis chinensis, 7-15 parts of safflower, 10-15 parts of vietnamese sophora root, 10-20 parts of peach kernel, 15-25 parts of angelica dahurica, 25-35 parts of selfheal, 15-25 parts of salvia chinensis, 6-15 parts of spina gleditsiae, 10-27 parts of glabrous sarcandra herb and 3-8 parts of blattaria. The invention has scientific and reasonable formula, can effectively resist cancers and improves the treatment effect of the cancers.
Description
Technical Field
The invention relates to the field of medical preparations, in particular to an anticancer traditional Chinese medicine composition.
Background
Cancer, also called malignant tumor, is a disease caused by the loss of normal regulation and hyperproliferation of body cells, which is a major medical problem threatening human life, according to statistics, the number of cancer patients in China is over 160 ten thousand each year, and the death rate of the cancer patients becomes the second cause of death after cardiovascular diseases.
With the research on the pathogenesis of the tumor, people have further knowledge on the world problem of the tumor, and the research shows that: tumors are a systemic disease. The method for treating cancer mainly comprises surgical excision, radiotherapy, chemotherapy and biological therapy, but because of the limitation of different procedures, the surgical excision enables an organism to generate a large amount of signal molecules for stimulating the proliferation and differentiation of cells, further enables most of the cells to be recruited to a wound part to participate in repair, and the signal molecules in the process can greatly stimulate the growth of the rest cancer cells, so that the recurrence rate is high, the toxic and side effects of the radiotherapy and the chemotherapy are serious, the organism has potential carcinogenic and mutagenic effects, and further most of middle and late stage cancer patients are difficult to be effectively and reasonably treated, but the whole body is extremely exhausted to accelerate the death process of the cancer patients. Therefore, the adoption of radical treatment traditional Chinese medicine therapy has profound significance for treating cancers.
Disclosure of Invention
The invention aims to overcome the problems in the prior art and provide an anticancer traditional Chinese medicine composition.
In order to achieve the above object, the present invention employs the following:
an anticancer traditional Chinese medicine composition comprises the following raw materials in parts by weight: 25-35 parts of salvia miltiorrhiza, 5-13 parts of Chinese fan palm, 6-12 parts of earthworm, 15-25 parts of dragon bone, 10-20 parts of camptotheca acuminata fruit, 5-15 parts of blackberry lily, 5-15 parts of garden balsam seed, 5-15 parts of princesplume ladysthumb fruit, 16-24 parts of clematis chinensis, 7-15 parts of safflower, 10-15 parts of vietnamese sophora root, 10-20 parts of peach kernel, 15-25 parts of angelica dahurica, 25-35 parts of selfheal, 15-25 parts of salvia chinensis, 6-15 parts of spina gleditsiae, 10-27 parts of glabrous sarcandra herb and 3-8 parts of blattaria.
Preferably, 30 parts of salvia miltiorrhiza, 10 parts of Chinese fan palm, 10 parts of earthworm, 20 parts of Gekko Swinhonis, 15 parts of common camptotheca fruit, 10 parts of blackberry lily, 10 parts of garden balsam seed, 10 parts of princesplume ladysthumb fruit, 20 parts of radix clematidis, 10 parts of safflower, 12 parts of vietnamese sophora root, 15 parts of peach kernel, 20 parts of radix angelicae, 30 parts of selfheal, 20 parts of Chinese sage herb, 10 parts of spina gleditsiae, 20 parts of glabrous sarcandra herb and 5 parts of blattaria.
Preferably, 25 parts of salvia miltiorrhiza, 5 parts of Chinese fan palm, 6 parts of earthworm, 15 parts of Gekko Swinhonis, 10 parts of common camptotheca fruit, 5 parts of blackberry lily, 5 parts of garden balsam seed, 5 parts of princesplume ladysthumb fruit, 16 parts of radix clematidis, 7 parts of safflower, 10 parts of vietnamese sophora root, 10 parts of peach kernel, 15 parts of radix angelicae, 25 parts of selfheal, 15 parts of Chinese sage herb, 6 parts of spina gleditsiae, 10 parts of glabrous sarcandra herb and 3 parts of blattaria.
Preferably, the traditional Chinese medicine composition comprises 35 parts of salvia miltiorrhiza, 13 parts of Chinese fan palm, 12 parts of earthworm, 25 parts of Gekko Swinhonis, 20 parts of common camptotheca fruit, 15 parts of blackberry lily, 15 parts of garden balsam seed, 15 parts of princesplume ladysthumb fruit, 24 parts of radix clematidis, 15 parts of safflower, 15 parts of vietnamese sophora root, 20 parts of peach kernel, 25 parts of radix angelicae, 35 parts of selfheal, 25 parts of Chinese sage herb, 15 parts of spina gleditsiae, 27 parts of glabrous sarcandra herb and 8 parts of bla.
The invention has the beneficial effects that: radix salviae miltiorrhizae, radix angelicae, selfheal, safflower and peach kernel, and has the effects of promoting blood circulation, dissipating blood stasis and relieving pain; the subprostrate sophora root is used as a guiding drug to guide the drug effect to the larynx and the esophagus; acute seed, fructus Polygoni orientalis, and radix Clematidis for opening throat and relieving obstruction; the rest herbs include semen Livistonae chinensis, Pheretima, Gekko Swinhonis, fructus Camptothecae Acuminatae, rhizoma Belamcandae, herba Salviae chinensis, spina Gleditsiae, herba Pileae Scriptae, and Blatta Seu Periplaneta, and have toxic materials killing effect on cancer cells. The raw material proportion has the synergistic function, and the traditional Chinese medicine composition has the bidirectional functions of directly inhibiting the growth and proliferation of cancer cells and enhancing the immunologic function, and can selectively inhibit and kill the proliferation of the cancer cells to achieve the anticancer effect through clinical research and test. The traditional Chinese medicine composition has quick effect on treating cancer, has no toxic or side effect, has obvious curative effect on laryngeal cancer, esophageal cancer, gastric cancer, intestinal cancer, rectal cancer, pancreatic cancer, liver cancer and the like, does not cause any influence on body cells, tissues, organ functions and hemogram during administration, does not need biochemical detection, is matched with radiotherapy and chemotherapy for use, and can reduce the side effect of the radiotherapy and the chemotherapy besides enhancing the curative effect.
Detailed Description
In order to more clearly illustrate the invention, the invention is further described below in connection with preferred embodiments. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and is not to be taken as limiting the scope of the invention.
Example one
Weighing the following raw materials in proportion: 30 parts of salvia miltiorrhiza, 10 parts of Chinese fanpalm seed, 10 parts of earthworm, 20 parts of longtianlong, 15 parts of common camptotheca fruit, 10 parts of blackberry lily, 10 parts of garden balsam seed, 10 parts of princesplume ladysthumb fruit, 20 parts of clematis root, 10 parts of safflower, 12 parts of vietnamese sophora root, 15 parts of peach kernel, 20 parts of dahurian angelica root, 30 parts of selfheal, 20 parts of Chinese sage herb, 10 parts of Chinese honeylocust spine, 20 parts of glabrous sarcandra herb and 5 parts of blattaria.
The preparation method comprises the following steps: selecting the required traditional Chinese medicine raw materials according to the parts by weight, respectively crushing the raw materials, sieving the crushed raw materials with a 80-mesh sieve, mixing the obtained powder with a proper amount of conventional pharmaceutical excipients, and preparing a pharmaceutically acceptable tablet (0.3 g/granule) according to a conventional forming process, wherein the traditional Chinese medicine raw material powder in the tablet accounts for more than 90 percent of the total weight, and the taking method of the tablet comprises the following steps: 2-3 times daily, 2-3 granules each time.
Example two
Weighing the following raw materials in proportion: 25 parts of salvia miltiorrhiza, 5 parts of Chinese fan palm, 6 parts of earthworm, 15 parts of longtianlong, 10 parts of common camptotheca fruit, 5 parts of blackberry lily, 5 parts of garden balsam seed, 5 parts of princesplume ladysthumb fruit, 16 parts of clematis root, 7 parts of safflower, 10 parts of vietnamese sophora root, 10 parts of peach kernel, 15 parts of dahurian angelica root, 25 parts of selfheal, 15 parts of Chinese sage herb, 6 parts of Chinese honeylocust spine, 10 parts of glabrous sarcandra herb and 3 parts of blattaria.
The preparation method comprises the following steps: the preparation method comprises the steps of firstly selecting the required traditional Chinese medicine raw materials according to the parts by weight, respectively crushing the raw materials, sieving the crushed raw materials with a 80-mesh sieve, mixing the obtained powder with conventional pharmaceutical excipients, and preparing the antiviral drug which can be pharmaceutically accepted into pills (50 mg/granule) according to a conventional forming process, wherein the traditional Chinese medicine raw material powder in the pills accounts for more than 90 percent of the total weight. The pill taking method comprises the following steps: 1-2 times daily, 1g each time.
EXAMPLE III
Weighing the following raw materials in proportion: 35 parts of salvia miltiorrhiza, 13 parts of Chinese fanpalm seed, 12 parts of earthworm, 25 parts of longtianlong, 20 parts of common camptotheca fruit, 15 parts of blackberry lily, 15 parts of garden balsam seed, 15 parts of princesplume ladysthumb fruit, 24 parts of clematis root, 15 parts of safflower, 15 parts of vietnamese sophora root, 20 parts of peach kernel, 25 parts of angelica dahurica, 35 parts of selfheal, 25 parts of Chinese sage herb, 15 parts of Chinese honeylocust spine, 27 parts of glabrous sarcandra herb and 8 parts of blattaria.
The preparation method comprises the following steps: the preparation method comprises the steps of firstly selecting required traditional Chinese medicine raw materials according to the parts by weight, respectively crushing the raw materials, sieving the crushed raw materials with a 80-mesh sieve, mixing the obtained powder with a proper amount of conventional pharmaceutical excipients, and preparing pharmaceutically acceptable traditional Chinese medicine granule (0.3 g/bag) according to a conventional forming process, wherein the traditional Chinese medicine raw material powder in the traditional Chinese medicine granule accounts for more than 95% of the total weight, and the traditional Chinese medicine granule has high purity and strong drug effect. The taking method of the electuary comprises the following steps: it is infused with water 2 times a day, 2-3 bags each time.
135 outpatients were received from 2016 to 2019, 78 men and 57 women; the age is 25-70 years, wherein the middle-aged and the elderly are mainly used, and the diagnosis is based on: image, pathology (cytology, histology).
And (4) judging the standard:
1) clinical symptoms: the clinical symptoms completely disappear and are cured, 6 clinical symptoms disappear, 4 clinical symptoms are obvious and effective; disappearance of less than 4 items, and no effect;
2) tumor mass: complete remission; reduction by 50% or more; reduction by 50% or enlargement by less than 25%; the expansion is more than 25.
And (4) observing results:
the tablets in example 1 were taken in this group of cases by the following method: the daily dosage is 3 times, 2 capsules each time, and the observation results are observed and recorded after each patient takes the medicine continuously for three months, wherein,
clinical symptoms: 7 cases are completely relieved, 37 cases are relieved, 56 cases are relieved, 18 cases below 4 items are relieved, 17 cases are ineffective, and the effective rate is 87%;
tumor mass: and (3) complete alleviation: case 0; reduction by 50% or more: 34 cases of; 50% reduction or less than 25% enlargement: 80 cases; expansion is more than 25: 21 cases, the effective rate is 84%.
In conclusion, the traditional Chinese medicine composition has a certain curative effect on relieving clinical symptoms; has certain curative effect on reducing cancerous lumps.
It should be understood that the above examples are given by way of illustration only and not by way of limitation of the embodiments of the present invention, and that various other modifications and variations of the embodiments described above will occur to those skilled in the art, which modifications and variations are within the spirit and scope of the invention.
Claims (4)
1. An anticancer traditional Chinese medicine composition is characterized by comprising the following raw materials in parts by weight: 25-35 parts of salvia miltiorrhiza, 5-13 parts of Chinese fan palm, 6-12 parts of earthworm, 15-25 parts of dragon bone, 10-20 parts of camptotheca acuminata fruit, 5-15 parts of blackberry lily, 5-15 parts of garden balsam seed, 5-15 parts of princesplume ladysthumb fruit, 16-24 parts of clematis chinensis, 7-15 parts of safflower, 10-15 parts of vietnamese sophora root, 10-20 parts of peach kernel, 15-25 parts of angelica dahurica, 25-35 parts of selfheal, 15-25 parts of salvia chinensis, 6-15 parts of spina gleditsiae, 10-27 parts of glabrous sarcandra herb and 3-8 parts of blattaria.
2. The anticancer Chinese medicinal composition according to claim 1, wherein the composition comprises 30 parts of red sage root, 10 parts of Chinese fan palm seed, 10 parts of earthworm, 20 parts of Gekko Swinhonis, 15 parts of common camptotheca fruit, 10 parts of blackberry lily, 10 parts of garden balsam seed, 10 parts of princesplume ladysthumb flower seed, 20 parts of Clematis chinensis, 10 parts of safflower, 12 parts of vietnamese sophora root, 15 parts of peach kernel, 20 parts of dahurian angelica root, 30 parts of selfheal, 20 parts of salvia chinensis, 10 parts of Chinese honeylocust spine, 20 parts of glabrous sarcandra herb and 5 parts of blattaria.
3. The anticancer Chinese medicinal composition as set forth in claim 1, wherein the anticancer Chinese medicinal composition comprises 25 parts of red sage root, 5 parts of Chinese fan palm seed, 6 parts of earthworm, 15 parts of Gekko Swinhonis, 10 parts of common camptotheca fruit, 5 parts of blackberry lily, 5 parts of garden balsam seed, 5 parts of princesplume ladysthumb fruit, 16 parts of clematis root, 7 parts of safflower, 10 parts of vietnamese sophora root, 10 parts of peach kernel, 15 parts of dahurian angelica root, 25 parts of selfheal, 15 parts of salvia chinensis, 6 parts of Chinese honeylocust spine, 10 parts of glabrous sarcandra herb and 3 parts of blattaria.
4. The anticancer Chinese medicinal composition as set forth in claim 1, wherein the composition comprises 35 parts of red sage root, 13 parts of Chinese fan palm seed, 12 parts of earthworm, 25 parts of Gekko Swinhonis, 20 parts of common camptotheca fruit, 15 parts of blackberry lily, 15 parts of garden balsam seed, 15 parts of princesplume ladysthumb fruit, 24 parts of Clematis chinensis, 15 parts of safflower, 15 parts of vietnamese sophora root, 20 parts of peach kernel, 25 parts of dahurian angelica root, 35 parts of selfheal, 25 parts of salvia chinensis, 15 parts of Chinese honeylocust spine, 27 parts of glabrous sarcandra herb and 8 parts of blattaria.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010994142.XA CN112022944A (en) | 2020-09-21 | 2020-09-21 | Anticancer Chinese medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010994142.XA CN112022944A (en) | 2020-09-21 | 2020-09-21 | Anticancer Chinese medicinal composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112022944A true CN112022944A (en) | 2020-12-04 |
Family
ID=73574709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010994142.XA Pending CN112022944A (en) | 2020-09-21 | 2020-09-21 | Anticancer Chinese medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112022944A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111053834A (en) * | 2020-01-23 | 2020-04-24 | 余嘉 | Traditional Chinese medicine liniment for treating esophagus cancer and preparation method thereof |
-
2020
- 2020-09-21 CN CN202010994142.XA patent/CN112022944A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111053834A (en) * | 2020-01-23 | 2020-04-24 | 余嘉 | Traditional Chinese medicine liniment for treating esophagus cancer and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 段汝钦: "《体质肿瘤学》", 30 September 2013, 天津科学技术出版社 * |
| 洪文旭，等: "《实用中医消化病学》", 31 December 1994, 天津科技翻译出版公司 * |
| 金国梁，等: "《防癌抗癌中药》", 31 August 2001, 上海科学技术出版社 * |
| 闫洪飞: "余桂清治疗食管癌经验", 《中国中医药信息杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041312B (en) | Traditional Chinese medicine composition with antineoplastic effect and preparation method and application thereof | |
| CN102078569B (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN102764371B (en) | Traditional Chinese medicine compound prescription for relieving radiotherapy side reactions and preparation method and application thereof | |
| CN113813347A (en) | Preparation method and process of compound paclitaxel anti-tumor capsule tablet | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN103933450A (en) | Traditional Chinese medicine composition for preventing or/and treating gastrointestinal diseases and preparation method of composition | |
| CN102389559A (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN112022944A (en) | Anticancer Chinese medicinal composition | |
| CN103191267B (en) | Traditional Chinese medicine composition for treating liver cancers | |
| CN101259180B (en) | Shenshe composition and preparation thereof | |
| CN114588240B (en) | Traditional Chinese medicine composition for treating colorectal cancer and preparation method and application thereof | |
| CN111388564B (en) | Traditional Chinese medicine for treating bradyarrhythmia | |
| CN114404547B (en) | Body resistance strengthening and blood stasis removing cream formula and application thereof | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN106943506B (en) | A pharmaceutical composition for treating climacteric syndrome, and its preparation method | |
| CN116115714A (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN104758749A (en) | Traditional Chinese medicine composition for treating liver cancer | |
| CN104940561A (en) | Traditional Chinese medicine preparation for treating eye diseases and preparing method of traditional Chinese medicine preparation | |
| CN1504231A (en) | Medicine for tumour | |
| CN1055020C (en) | Method for preparing anti-tumour Chinese medicinal liquor | |
| CN118217370A (en) | Compound taxol broad-spectrum anticancer Chinese medicinal preparation and its preparation method | |
| CN113368211A (en) | Traditional Chinese veterinary medicine composition for treating tumors of dogs and cats and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201204 |